Clinical, histopathological and therapeutic considerations in non-neoplastic abnormal uterine bleeding in menopause transition.

Corniţescu FI, F. Cornitescu, F I Corniţescu, Florentina Tănase, Tănase F, F. Tanase, Simionescu C, Cristiana Simionescu, Dominic Gabriel Iliescu, D Iliescu
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie · 2011 · vol. 52(3) , pp. 759–65 · PMID:21892516 · W2395642866
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

This retrospective study analyzed 256 women experiencing abnormal uterine bleeding during menopause transition, finding leiomyomas were the most common histopathological finding and progesterone therapy effectively treated bleeding and prevented endometrial cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

With the decline of ovarian hormonal function, from the fifth decade of life, women enter the menopause transition, during which bleeding becomes irregular in duration and time of occurrence. Secondary to ovarian dysfunction, developmental and maturation endometrial anomalies occur, which are clinically translated by abnormal uterine bleeding, which in many cases at this age can be caused by organic lesions (fibroma, polyps, endometritis, endometrial hyperplasia, adenomyosis, etc.). The retrospective study included a total of 256 patients with abnormal uterine bleeding in menopause transition. Statistics showed that the incidence of these types of bleeding increases with age (64.5%) and parity (30.5%), with symptoms consisting mostly in different clinical forms of abnormal uterine bleeding (62.1%), and leiomyomas prevailing at histopathological examination (49.6%). Progesterone replacement therapy was the first therapeutic choice for correcting these types of bleeding. Progesterone therapy is useful not only for therapeutic purposes to amend the bleeding, but also as a precaution against the development of endometrial carcinoma. Progestogens cancel the proliferative and mitogenic effect of estrogens, even when administered in sequential regimen 10-12 days per month.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Menopause Progesterone Progestins Uterine Hemorrhage Uterine Hemorrhage Adult Endometrial Hyperplasia Endometrial Hyperplasia Female Humans Middle Aged Progesterone Progestins Retrospective Studies Uterine Hemorrhage Uterine Hemorrhage

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (3)

References (13)

Cited by (3)

Source provenance

europepmc
last seen: 2026-09-25T06:10:54.854274+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:16:35.898691+00:00
License: CC0 · commercial use OK